Telix upgrades 2025 revenue guidance after 53% lift in September quarter
Make us a preferred source
Make us a preferred source on Google
The news: Telix Pharmaceuticals has upgraded its revenue guidance for 2025 after delivering a 53% year-on-year gain in unaudited group revenue in the September quarter.
During the quarter, the company experienced increased sales of prostate cancer cell imaging agents Gozellix and Illuccix.
The numbers: Telix’s upgraded FY25 revenue guidance is USD800 million ($1.2 billion) and USD820 million, up from USD770 million and USD800 million.
The company also reported Q3 unaudited group revenue of about USD203 million.
Telix also confirmed its research and development expenditure guidance investment range is expected to be 20% to 25% higher in 2025 than in 2024.
The context: The guidance change reflects product sales of prostate cancer imaging agents Illuccix and Gozellix as well as 11 months of revenue contribution from RLS Radiopharmacies, which was acquired at the end of January.
The source: ASX
